Key Metrics 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Sterling Biotech Ltd (STERLINBIO)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 512299 NSE: STERLINBIO Chemicals | Small Cap | Sterling Biotech Share Price
BSE Share Price
Not Listed
Not Listed
Sterling Biotech Ltd (STERLINBIO)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 512299 NSE: STERLINBIO Chemicals | Small Cap | Sterling Biotech Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹21 Cr.
Current Price
₹0
52-Week Low / High
₹1 / 1
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
48
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
5.2%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
24.64%
Pledged shares (%) of Promoter's holding (%)
62.29%
Reserves
-
Equity
₹27.2 Cr.
Face Value
₹1
All Time Low / High
₹0.67 / 262.45
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation ⓘ
| Dec'11 | Dec'12 | Dec'13 | Dec'14 | Mar'16 | Mar'17 | Mar'18 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 4.6% | -1.7% | -2.9% | -3.1% | -3.6% | -3% | -12.5% | -5.7% | 385.8% | -0.7% | - |
| Value Creation Index ⓘ | -0.7 | -1.1 | -1.2 | -1.2 | -1.3 | -1.2 | -1.9 | NA | NA | NA | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 1,662 | 835 | 718 | 667 | 419 | 368 | 352 | 410 | 434 | 457 | 408 |
| Sales YoY Gr. | - | -49.8% | -14% | -7.1% | -37.2% | -12.1% | -4.4% | 16.3% | 6% | 5.2% | - |
| Adj EPS ⓘ | 3.2 | -13 | -15 | -16.8 | -13.2 | -15.2 | -17.1 | -8.7 | 2.4 | 0.1 | -10.9 |
| YoY Gr. | - | -503.4% | NA | NA | NA | NA | NA | NA | NA | -97.9% | - |
| BVPS (₹) ⓘ | 93 | 69.8 | 54.9 | 38.1 | 48.9 | 46.9 | 10.1 | -210.6 | 1.4 | 1.4 | -79.7 |
| Adj Net Profit ⓘ | 86.5 | -349 | -401 | -458 | -360 | -412 | -465 | -236 | 1,562 | 33.5 | -295 |
| Cash Flow from Ops. ⓘ | 370 | 811 | 172 | 256 | 53.6 | 1 | -32.8 | 32.4 | -15.7 | 48.8 | - |
| Debt/CF from Ops. ⓘ | 11.5 | 4.5 | 22.6 | 18 | 98 | 7326.3 | -228.4 | 249 | 0 | 0.2 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -13.4% | 1.7% | 9.1% | 5.2% | ||||
| Adj EPS ⓘ | -37.1% | NA | NA | -97.9% | ||||
| BVPSⓘ | -37.4% | -51.1% | -48.7% | -2.1% | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Dec'11 | Dec'12 | Dec'13 | Dec'14 | Mar'16 | Mar'17 | Mar'18 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 3.5 | -16 | -24 | -22.8 | -21.4 | -28.1 | -59.9 | 8.7 | -64.6 | 3.8 | 27.7 |
| Op. Profit Mgn % ⓘ | 38.4 | 17.7 | 13.2 | 12 | 12.3 | 3.4 | 4 | 8.4 | 13.5 | 14.6 | 9 |
| Net Profit Mgn % ⓘ | 5.2 | -41.8 | -55.8 | -68.6 | -86 | -112 | -131.9 | -57.7 | 359.6 | 7.3 | -72.4 |
| Debt to Equity ⓘ | 1.7 | 1.9 | 2.6 | 1.8 | 4 | 5.5 | 27.2 | -1.4 | 0 | 0 | - |
| Working Cap Days ⓘ | 458 | 801 | 742 | 724 | 791 | 1,097 | 853 | 284 | 150 | 166 | 47 |
| Cash Conv. Cycle ⓘ | 325 | 630 | 586 | 524 | 504 | 669 | 427 | 92 | 97 | 103 | -1,606 |
Valuation of Sterling Biotech - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 62.29 | 62.29 | 62.29 | 62.29 | 62.29 | 62.29 | 62.29 | 62.29 | 62.29 | 62.29 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Sterling Biotech Ltd FAQs
The current trading price of Sterling Biotech on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Sterling Biotech stood at ₹20.96 Cr
The latest P/E ratio of Sterling Biotech as of 31-Dec-1969 is 0.00.
The latest P/B ratio of Sterling Biotech as of 31-Dec-1969 is -0.01.
The 52-week high of Sterling Biotech is ₹0.85 and the 52-week low is ₹0.77.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sterling Biotech is ₹408 ( Cr.) .
Data is not available for this company.
The key valuation ratios of Sterling Biotech Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.
No data found
About Sterling Biotech Ltd
Working with and developing any opportunity into reality is a mindset at Sterling Group. Sterling Biotech Limited with its new thinking, new capabilities and sense of urgency aspires to “Earn trust, every moment” of its partners, collaborators, stake holders and customers.
The company is focusing to commercialize Active Pharmaceutical Ingredient (API) and make it available at competitive prices to its global customers.
The company’s capabilities include state of art research centre, advance pilot plant for scale up studies, modern facility of bioreactors and range of down streaming process equipments. All these are coupled with dedicated and qualified work force, well equipped quality control laboratory and quality assurance systems
The company strives to become leaders in API pharmaceutical area by developing state of the art facility for research and development, contract manufacturing of active pharmaceutical ingredients. It builds quality in every aspect of manufacturing with particular laid down emphasis based on current Good Manufacturing Practices.
The company is committed to scaling new heights and creating new dimensions in Fermentation based API and Synthetic API. This way it shall support aspiration to “Live better and Live longer”.
The company’s manufacturing facility at Masar, Gujarat, is at par with international standards. It complies with cGMP norms complying to the standards of WHO and is in the process of getting CEP for the active pharmaceutical ingredient Epirubicin, Lovastatin
This adequately reflects Sterlings commitment towards quality. Efforts to attain such standards have also opened the key to gain foothold in the regulated and semi regulated markets throughout US and Europe
Business area of the company
The company is engaged in the manufacturing of Pharma Grade Gelatine & Di-Calcium Phosphate and other Pharma products. The Company has presence in both domestic and international markets.
Products
- Simvastatin Ammonium Salt
- Lovastatin
- Daunorubicin HCL
- Doxorubicin HCL
- Epirubicin HCL
- Idarubicin HCL
- Zoledronic Acid
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
